IDiyas

For the Inventor, By the Inventor

Waltham, MA, United States of America

Christopher Todd Baker

USPTO Granted Patents = 16 

Average Co-Inventor Count = 8.0

ph-index = 8

Forward Citations = 326(Granted Patents)


Location History:

  • Bedford, MA (US) (2003 - 2007)
  • Waltham, MA (US) (1999 - 2011)

Company Filing History:

goldMedal16 out of 1,149 
 
Vertex Pharmaceuticals, Inc.
 patents

Years Active: 1999-2011

Loading Chart...
16 patents (USPTO):
1. 7919523 - Inhibitors of aspartyl protease (2011-04-05),
2. 7592368 - Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors (2009-09-22),
3. 7442718 - Inhibitors of aspartyl protease (2008-10-28),
4. 7169798 - Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases (2007-01-30),
5. 7056944 - Pyrazole compositions useful as inhibitors of erk (2006-06-06),
6. 6838474 - Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors (2005-01-04),
7. 6699865 - Pyrazole compositions useful as inhibitors of ERK (2004-03-02),
8. 6693108 - Inhibitors of c-JUN N terminal kinases (JNK) and other protein kinases (2004-02-17),
9. 6617350 - Inhibitors of aspartyl protease (2003-09-09),
10. 6593357 - Pyrazole compositions useful as inhibitors of ERK (2003-07-15),
11. 6559137 - Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors (2003-05-06),
12. 6528509 - Pyrazole compositions useful as inhibitors of ERK (2003-03-04),
13. 6436989 - Prodrugs of aspartyl protease inhibitors (2002-08-20),
14. 6319946 - Inhibitors of aspartyl protease (2001-11-20),
15. 5945413 - Aspartyl protease inhibitors (1999-08-31),

Title: Christopher Todd Baker: Innovator in HIV Protease Inhibition

Introduction

Christopher Todd Baker is a prominent inventor based in Waltham, MA (US), known for his significant contributions to the field of pharmaceutical sciences. He holds a total of 16 patents, showcasing his innovative approach to developing treatments for viral infections, particularly HIV.

Latest Patents

Among his latest patents, Baker has developed inhibitors of aspartyl protease, which represent a novel class of sulfonamides. These inhibitors are specifically designed to target HIV aspartyl protease, characterized by unique structural and physicochemical features. The invention includes pharmaceutical compositions that utilize these compounds, making them particularly effective against HIV-1 and HIV-2 protease activity. Additionally, Baker has created sulfonamide derivatives as prodrugs of aspartyl protease inhibitors. These prodrugs are designed to enhance aqueous solubility and oral bioavailability, ultimately improving patient compliance by reducing the pill burden.

Career Highlights

Baker's career is marked by his role at Vertex Pharmaceuticals, Inc., where he has been instrumental in advancing research and development in antiviral therapies. His work has not only contributed to scientific knowledge but has also had a profound impact on patient care and treatment options for those affected by HIV.

Collaborations

Baker has collaborated with notable colleagues, including Michael Robin Hale and Andrew Spaltenstein, to further enhance the research and development of innovative pharmaceutical solutions.

Conclusion

Christopher Todd Baker's contributions to the field of HIV protease inhibition exemplify the importance of innovation in pharmaceutical research. His patents and ongoing work continue to pave the way for more effective treatments for viral infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…